
|Videos|March 14, 2022
What the re:Vive 2.0 platform may mean for the future of vision diagnostics
Author(s)Sheryl Stevenson
Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.
Advertisement
Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
FDA approves NDA labeling supplement allowing re-administration of iDose TR
3
Opus Genetics launches phase 1/2 MERTK gene therapy trial
4
Dr. Mali’s top 5 predictions in ophthalmology for 2026
5



























